Stay updated on Obicetrapib + Ezetimibe Adjunct in HIS Therapy Clinical Trial
Sign up to get notified when there's something new on the Obicetrapib + Ezetimibe Adjunct in HIS Therapy Clinical Trial page.

Latest updates to the Obicetrapib + Ezetimibe Adjunct in HIS Therapy Clinical Trial page
- Check5 days agoChange DetectedThe Record History now lists revision v3.3.4 added and revision v3.3.3 removed from the revisions list.SummaryDifference0.1%

- Check12 days agoNo Change Detected
- Check19 days agoNo Change Detected
- Check26 days agoChange DetectedFooter updates: added Revision: v3.3.3 and removed the HHS Vulnerability Disclosure link, along with removal of Revision: v3.3.2 from the history. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.2%

- Check48 days agoChange DetectedNew revision v3.3.2 appears in the Record History, superseding v3.3.1.SummaryDifference0.1%

- Check55 days agoChange DetectedRevision: v3.3.1 was added to the page history and Revision: v3.2.0 was removed.SummaryDifference0.1%

- Check63 days agoChange DetectedThe government funding notice banner was removed from the page, removing the lapse-in-funding message previously shown. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.8%

- Check77 days agoChange DetectedThe Record History shows updates to the ROSE2 trial across multiple versions, including recruitment and study status changes in 2022 and a 2024 update that adds/adjusts Study Status, Outcome Measures, and related sections, along with updates to Contacts/Locations and Study Design.SummaryDifference0.1%

Stay in the know with updates to Obicetrapib + Ezetimibe Adjunct in HIS Therapy Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Obicetrapib + Ezetimibe Adjunct in HIS Therapy Clinical Trial page.